" class="no-js "lang="en-US"> Rivka Kreitman - Medtech Alert
Monday, May 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Rivka Kreitman

Rivka Kreitman

About Rivka Kreitman

Rivka is a Pharmaceutical Executive who spent over 26 years at Teva Pharmaceuticals. During her tenure at Teva, Rivka held various roles including Head of Global Innovative Research and Development (IR&D), where she managed a group of 700 researchers focusing on CNS and Autoimmune. Rivka also led Search and Evaluation, and was Head of Global Speciality Regulatory Affairs at Teva. Rivka earned her PhD at the Weizmann Institute of Science (Biochemistry) and completed postdoctoral work at Princeton University (Molecular Biology).

Related Story

Artificial Intelligence

 NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML | Pharmtech Focus

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML

July 29 2022

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company […]